PD-1 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) receptors inhibit the anti-tumor function of immune cells by blocking CD3/CD28 signaling, which is mediated by the up-regulation of glucose metabolism and interaction with intracellular pathways [204, 205]. Here, CD28 is linked to neoplasm.